LOGIN
ID
PW
MemberShip
2025-07-19 08:00
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Policy
[Reporter's View] A separate fund for new orphan drugs
by
Lee, Jeong-Hwan
Jul 18, 2025 06:36am
Will the 'establishment of a separate fund,' considered one of the ways to improve patient access to expensive, rare, and intractable disease drugs, become even more difficult with the inauguration of the Lee Jae Myung administration? Jung Eun-kyung, the candidate for Minister of Health and Welfare (MOHW), who is facing a parliamentary co
Policy
Will the external reference pricing reevals gain momentum?
by
Lee, Jeong-Hwan
Jul 18, 2025 06:35am
Eun-Kyung Jeong, nominee for Minister of Health and Welfare, said that ¡°it is important to manage drug prices at an appropriate level given the limited health insurance resources¡± regarding the post-marketing price review system to lower generic drug prices through ¡°external reference pricing evaluations,¡± suggesting the possibility of i
Policy
Jung Eun-kyung views "orphan disease fund establishment"
by
Lee, Jeong-Hwan
Jul 18, 2025 06:35am
Jung Eun-kyung, the candidate for Minister of Health and Welfare (MOHW), has expressed skepticism regarding the establishment of a separate fund to improve the National Health Insurance reimbursement rate for treatments for expensive, rare (orphan), and severe diseases. The rationale is that if the required financial scale for reimbursing
Policy
When will Keytruda¡¯s reimb be reviewed by DREC?
by
Lee, Tak-Sun
Jul 17, 2025 06:13am
Attention is focused on when Keytruda, for which reimbursement standards were set for 11 indications in February, will be submitted to the Drug Reimbursement Evaluation Committee (DREC) for review. This is because, although the reimbursement standards were established by the Health Insurance Review and Assessment Service's Cancer Review C
Policy
Will the general diabetes criteria be revised after 14 yrs?
by
Lee, Tak-Sun
Jul 16, 2025 06:09am
The National Health Insurance Service (NHIS) is currently reviewing a comprehensive revision of the general principles for diabetes drug reimbursement criteria, which have been in place for 14 years. It is garnering significant attention from the industry. Following recent trends, significant changes are anticipated, including the remova
Policy
Gov't pursues 'project to produce unstable supply drugs'
by
Lee, Jeong-Hwan
Jul 15, 2025 06:08am
The Ministry of Health and Welfare (MOHW) plans to continue its project of providing government funding for the production of drugs with unstable supply. The MOHW plans to proceed with the currently budgeted project to support one item, while also working to secure additional budget to support more items. A MOHW official recently met w
Policy
How Trodelvy was applied flexible ICER for innovativeness
by
Lee, Tak-Sun
Jul 14, 2025 06:04am
The ADC breast cancer drug Trodelvy (sacituzumab govitecan, Gilead), which was reimbursed in June for triple-negative breast cancer, was the first case in which the ICER (incremental cost-effectiveness ratio) threshold was flexibly applied in recognition of its innovation. So how did the Drug Reimbursement Evaluation Committee (DREC) of t
Policy
Orphan drug 'Bylvay Cap' wins reimb approval after reeval
by
Lee, Tak-Sun
Jul 14, 2025 06:03am
'Bylvay Cap,' which is being considered for the expedited reimbursement listing process as a designated drug for 'Pilot Project for Integration of Product Approvals, Reimbursement Coverage Reviews, and Drug Price Negotiations,' received reimbursement appropriateness decision after reevaluation. Consequently, Bylvay Cap will be subjected to ne
Policy
Will drugs subject to reimbursement reevals be expanded?
by
Lee, Tak-Sun
Jul 11, 2025 06:11am
The government is reportedly planning to tighten the selection criteria ahead of the second phase of the drug reimbursement adequacy reevaluations, which is set to begin next year. As a result, it is expected that the number of ingredients subject to reassessment may be expanded. According to industry sources on the 10th, the Health In
Policy
Pfizer discontinues the supply of 'Viviant' in KOR
by
Lee, Tak-Sun
Jul 11, 2025 06:09am
Pfizer announced of discontinuing the supply of its 'Viviant Tab (bazedoxifene acetate)' in Korea. They stated that supply discontinuation is due to the difficulty in securing a stable and continuous supply. Viviant had previously been out of stock in May due to delays in the manufacturing site. An analysis suggests that Viviant's marke
1
2
3
4
5
6
7
8
9
10
>